8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Mar 23, 2026·SEC
Xilio Therapeutics, Inc.(XLO)Earnings, Financials & Key Ratios
XLO•NASDAQ
$8.75
Price updated Jun 25, 2026
AboutXilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$44M+589.9%
- EBITDA-$40M+31.4%
- Net Income-$35M+39.8%
- EPS (Diluted)-4.19+72.5%
- Gross Margin96.48%-3.5%
- EBITDA Margin-92.4%+90.1%
- Operating Margin-95.92%+90.0%
- Net Margin-80.05%+91.3%
- ROE-132.53%+38.1%
XLO Price & Volume
Xilio Therapeutics, Inc. (XLO) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Dependency Drives Volatile Financial Performance
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Xilio Therapeutics operates an asset-light, high-risk biotechnology model heavily reliant on lumpy, milestone-based partnership revenue to fund its intensive R&D pipeline. While the company maintains a cash position of $150.3 million as of 2026Q1, the lack of sustainable commercial revenue and a history of $428.3 million in accumulated losses create significant long-term solvency concerns. Investors should monitor the company's ability to achieve clinical milestones, as any failure in trial execution could necessitate further dilutive equity financing to sustain operations."
Verdict Logic
the company's reliance on non-recurring revenue to offset a $22.9 million quarterly free cash flow burn rate presents an unsustainable risk profile for long-term capital appreciation.
XLO Growth Metrics
Xilio Therapeutics, Inc. (XLO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM476.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM56.13%
Return on Capital
10 Years-85.68%
5 Years-82.89%
3 Years-97.53%
Last Year-59.04%
XLO Recent Earnings
Xilio Therapeutics, Inc. (XLO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (38%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.58+12.1%
$0.66
Rev
$13M+48.5%
$9M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.85+49.4%
$1.68
Rev
$14M+25.6%
$11M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.03+93.3%
$0.45
Rev
$19M+2.3%
$19M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.16+85.5%
$1.10
Rev
$8M-56.6%
$19M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.58vs $0.66+12.1% | $13Mvs $9M+48.5% |
| Q2 2026 | Mar 23, 2026 | $0.85vs $1.68+49.4% | $14Mvs $11M+25.6% |
| Q4 2025 | Nov 13, 2025 | $0.03vs $0.45+93.3% | $19Mvs $19M+2.3% |
| Q3 2025 | Aug 14, 2025 | $0.16vs $1.10+85.5% | $8Mvs $19M-56.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Xilio Therapeutics, Inc. (XLO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.75 | $1.43B | -2.09 | 589.88% | -80.05% | -132.53% | — | |
| $2.78 | $198.9M | -1.97 | — | — | -30.9% | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $2.88 | $119.93M | -847.06 | 10.37% | 52.16% | — | — | |
| $34.09 | $2.27B | -8.74 | -78.63% | -34596.22% | -50.72% | — |
Compare XLO vs Peers
Xilio Therapeutics, Inc. (XLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XLO SEC Filings & Documents
Xilio Therapeutics, Inc. (XLO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XLO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XLO Frequently Asked Questions
Xilio Therapeutics, Inc. (XLO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Xilio Therapeutics, Inc.'s revenue?
Xilio Therapeutics, Inc. (XLO) reported $53.5M in revenue for fiscal year 2025.
How fast is Xilio Therapeutics, Inc. growing?
Xilio Therapeutics, Inc. (XLO) grew revenue by 589.9% over the past year. This is strong growth.
Is XLO profitable?
Xilio Therapeutics, Inc. (XLO) reported a net loss of $31.3M for fiscal year 2025.
Dividend & Returns
What is XLO's return on equity?
Xilio Therapeutics, Inc. (XLO) has a return on equity (ROE) of -132.5%. Negative ROE indicates the company is unprofitable.
What is Xilio Therapeutics, Inc.'s free cash flow?
Xilio Therapeutics, Inc. (XLO) had negative free cash flow of $57.4M in fiscal year 2025, likely due to heavy capital investments.